Abstract: Methods for improving the drying yield and stability of RSV vaccines comprising a highly thermolabile enveloped live virus and/or one or more RSV protein subunits, are described. Methods for rapid drying of RSV formulations containing between 17.5% and 60% w/w of a non-polymeric sugar and using either conduction or radiation dominant drying mechanisms, are disclosed. The disclosed methods provide for; 1) a dried RSV formulation with improved stability profile; 2) faster drying; and 3) integration of dried RSV into a primary device (such as dual chamber cartridges, foil-pouch devices etc.), pre- as well as post-drying.

Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media.

Abstract: The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

Abstract: Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.

Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.

Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.

Abstract: The invention is directed to a compound according to the formula [1] wherein R1 and R2 are branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or O and R is —OH or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof. The invention is also directed to process for preparing said compound and the use of said compound as an adjuvant. The invention is also directed to a composition comprising said compound and the use of said composition, for example as a vaccine composition.

Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.

Abstract: One side-effect arising from the use of antibodies against TNF receptor family members as therapeutics can be liver damage which precludes the completion of clinical trial. A novel LT-dependent pathway is described that mediates liver cell injury in several disease models.

Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.

Abstract: The invention provides a method for stabilizing antibody at high concentrations using albumin; use of albumin to stabilize high concentration antibody compositions; a stable high concentration antibody composition and uses thereof. The invention also provides a method to control or reduce viscosity and/or injection force of an antibody composition.

Abstract: There are provided, inter alia, compositions including a scintillator nanocrystal linked to a chemical agent moiety through a scintillator-activated photocleavable linker, and methods of use thereof.

Abstract: The design of biodegradable magnetic nanoparticles for use in in-vivo biomedical applications. The particles can include Fe in combination with one or more of Mg, Zn, Si, C, N, and P atoms or other particles. The nanoparticles can be degraded in-vivo after usage. The nanoparticles can cease heating upon reaching a predetermined temperature or other value.

Abstract: Provided herein are lanthanide-containing upconverting nanoparticles, methods of their preparation, compositions, and methods of using the same. The polymers and compositions provided herein may be used, for example, in photodynamic therapy.

Abstract: The present invention provides a subcutaneous injection product for cattle for inducing superovulation characterized by comprising aluminum hydroxide gel and an efficient amount of a gonadotropin, wherein the concentration of the aluminum hydroxide is, in terms of the amount of aluminum, higher than or equal to 0.2 mg/mL and lower than 1.0 mg/mL, which is a subcutaneous injection product that is useful for producing good calves and that can induce superovulation in a cow by a single administration. The present invention also provides a method for producing good calves undergoing steps of subcutaneously injecting the aforementioned injection product into a cow to thereby induce superovulation, inducing estrus in the cow, conducting artificial insemination, and then collecting fertilized eggs.

Abstract: A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed.

Abstract: Compositions useful for making dosage forms capable of dissolving or disintegrating in less than 10 seconds without the need for conventional disintegrants and methods making and using the same are disclosed.

Abstract: A Chinese herbal medical composition in the form of jelly, wherein a Chinese herbal medicine is contained in a base containing at least one substance selected from the group consisting of carrageenan, carob bean gum and xanthan gum and not containing phosphate buffer. The Chinese herbal medical composition hardy muses syneresis, is superior in the preservative stability, is broadly applicable to a Chinese herbal medicine and is orally taken without taking care of the bitter of a Chinese herbal medicine.

Abstract: Certain embodiments of the present invention provide methods, of treating a skin abnormality in a mammalian subject, that involve introducing, into a vasculature of the subject, red blood cells (RBCs) that comprise a photosensitive compound; and then permitting to pass a time-period sufficient for some of the RBCs to enter a region of the subject that comprises the skin abnormality; and then exposing RBCs in the region to an amount of radiation energy sufficient to result in the photosensitive compound mediating a hyperthermic therapy, a thermal therapy, an oxygen singlet therapy, a radical molecule therapy, or a combination thereof on the skin abnormality. In some embodiments, the photosensitive compound comprises a dye and is substantially encapsulated within the RBCs. In some embodiments, the radiation energy consists essentially of radiation wavelengths absorbed substantially more efficiently by the photosensitive compound than by an epidermal tissue of the subject.

Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.

Abstract: A pegylated artesunate derivative, a pharmaceutical composition and uses thereof, the pegylated artesunate derivative is represented by the general formula (I): The pegylated artesunate derivative has activity comparable to that of artesunate, increased water solubility and stability, and an extended half-life in vivo.

Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.

Abstract: New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin.

Abstract: The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.

Abstract: The present invention relates to methods and compositions for the treatment of cancer. Some embodiments include methods of treating cancer comprising administering a chemotherapeutic agent associated with albumin, administering a second chemotherapeutic agent; and administering a third chemotherapeutic agent.

Abstract: A compound which is selected from A: and salts and solvates thereof.

Abstract: A compound which is selected from A: A O OO O O O I O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N B: 5 B O OO O O O Br O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N; and C C O O N H N H O N H OO OO O O N O OO O O O O NH O O O O O O O O N H N H N H OO OH H O N N OO OH H N N; and salts and solvates thereof.

Abstract: Conjugates of specific PBD dimers with an antibody that binds to CD22, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1.

Abstract: Glycoproteins comprising a glycan of the formula (102) are disclosed; wherein b is 0 or 1; the GlcNAc residue optionally fucosylated; and Su(A)x is a sugar derivative comprising x functional groups A, wherein x is 1, 2, 3 or 4 and A is independently selected from the group consisting of an azido group, a keto group, an alkynyl group, a thiol group, a halogen, a sulfonyloxy group, a halogenated acetamido group, a mercaptoacetamido group and a sulfonylated hydroxyacetamido group. Protein-conjugates having glycoproteins according to the invention conjugated to a molecule of interest (e.g., an active substance) are also disclosed. Examples include modified antibodies, antibody-conjugates, and antibody-drug conjugates (ADCs). Processes for the preparation of the modified glycoproteins according to the invention and methods for the preparation of a protein-conjugate according to the invention are mentioned.

Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

Abstract: The present invention relates to a stable formulation particularly suitable for the anti-mesothelin immunoconjugate MF-T-SPDB-DM4. The described stable aqueous formulation comprising MF-T-SPDB-DM4 is directly suitable for therapeutic applications and for subsequent lyophilization. The lyophilized powder can be reconstituted with water to create a reconstituted solution which is again suitable for therapeutic applications. It is a further object to provide a stable reconstituted protein formulation which is suitable for therapeutic administrations.

Abstract: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.

Abstract: This document provides methods and materials related to treating lymphomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD20 polypeptide antibody complexes) to treat lymphomas are provided.

Abstract: The present invention provides a shielded biologic therapeutic comprising a biologic therapeutic which is covalently and cleavably bound to one or more nanoparticle, with a plurality of polymer chains bound to the or each nanoparticle.

Abstract: The invention relates to creped prebiotic tissue products. The tissue products comprise prebiotics in sufficiently high amounts to have a prebiotic effect in use, without negatively affecting tissue product properties, such as tensile strength, stiffness or softness. Thus, in certain embodiments the present invention provides soft, durable creped prebiotic tissue products that are able to improve the growth of healthy bacteria such as Bifidobacterium spp. or Lactobacillus spp. without promoting growth of enteropathogenic bacteria. The tissue products provide these benefits yet have a GMT greater than about 500, a Stiffness Index less than about 20 and a TS7 value less than about 10.

Abstract: A lipid particle can include a cationic lipid. The cationic lipid can include one or more hydrophobic tails, which can include one or more sites of unsaturation. The sites of unsaturation can include cycloalkyl groups, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl groups. The lipid particle is suitable for delivering an active agent.

Abstract: The present disclosure is directed to methods and a diagnostic kit for producing pericyte information from a subject for identifying and/or treating a subject condition. In one aspect, a method for identifying a subject condition is provided. The method includes administering intravenously to a subject an effective amount of a solution comprising fluorescent markers to selectively label a plurality of pericytes in the subject's body. The method also includes acquiring fluorescence signals originating from labeled pericytes to produce pericyte information associated with tissues of the subject's body. The method further includes generating a report identifying a subject condition using the pericyte information. In some aspects, a treatment may be adapted using the identified subject condition.

Abstract: A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.

Abstract: The invention relates to lipid polymeric patchy particles formed by nanoprecipitation and emulsification processes, utilizing a polymer blend including the polymer, solvent and lipid-PEGylated functional groups. More particularly, the invention relates to synthesizing particles having different or pre-selected morphologies (internal and external) and physicochemical properties. It has been found that the shear stress experienced by the polymer blend during emulsification can impart certain external and internal morphology and physicochemical properties to the resulting particles. Further, the one or more patches of the particles can be functionalized, such as, with gold nanoparticles, for use of the particles, in particular, in photoacoustic and ultrasound imaging.

Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.

Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.

Abstract: Methods and solutions are describes whereby radiopharmaceutical radium-224 solutions are added complex for scavenging daughter nuclide, which may enhance the overall targeting and reduces uptake of daughter nuclide in normal tissues and cells. This is accomplished without reducing the bone targeting ability of radium. The methods and solutions are convenient to use since the complexation of daughter nuclide can be done in situ in a ready to use radiopharmaceutical solution or, depending on the activity concentration, in a simple kit format by mixing two solutions and store the mixture for typically 1 minute to a few hours before administration to a patient. The use of targeted chelate scavengers for 224Ra daughter nuclide opens up the possibility for using 224Ra based solutions for medical treatments.

Abstract: A sanitizer system and method of use is disclosed. The sanitizer system quickly sanitizes and cools targeted objects and secures the targeted sanitized objects for later use, without the need to transfer the objects to a separate container. In one embodiment, the sanitizer system comprises a cassette having a body and a removable lid that, when joined, form an airtight chamber for containing an object for sterilization. A pressure control element of the system is configured to fluidly engage with the cassette to produce a pressure-controlled environment within the airtight chamber. A heating element of the system, which is interconnected and in thermal communication with the airtight chamber, is configured to provide heat to the airtight chamber. The chamber temperature is raised to a desired temperature for a period of time sufficient to sanitize the object. A cooling element of the system is configured to cool the chamber and the object.

Abstract: A system for sanitizing a tray table may include a sanitation assembly operatively coupled to the tray table. The sanitation assembly includes an ultraviolet (UV) light source configured to emit UV light, and a sanitation control unit operatively coupled to the UV light source. The sanitation control unit operates the UV light source to emit the UV light onto the tray table when the tray table is secured in an upright position, and prevents the UV light source from emitting the UV light when the tray table is not secured in the upright position.

Abstract: Curtains are provided which have fastener/s and, in some cases, strut/s arranged along a screen. The strut/s extend to elevation/s below and/or above the fastener/s. An upper strut may have a lower degree of stiffness than a lower strut. In some cases, the fastener/s are arranged at least 20 inches from the screen's upper edge. Systems are described which include a disinfection apparatus and any of such curtains. Other systems include any of such curtains attached to an edge of a room divider. Easily assembled and disassembled room dividers are described which include cord/s and/or pole/s, installed or portable device/s for supporting the cords/poles, and fasteners for attaching a curtain to the cords/poles. A disinfection apparatus is described which includes a shield extending to an elevation at least two feet above a germicidal light source and borders at least one third of a continuous region surrounding the germicidal light source.

Abstract: A storage and sterilizing case shaped and dimensioned for storing a tattoo machine therein. The case has a cover and a base. The cover is connected to the base via a hinge securing the cover to the base along adjacent edges thereof. The base includes a tray for supporting the tattoo machine within the case. The interior of the case is provided with an electronic circuit board and at least one ultraviolet light.

Abstract: An unpowered pressurized chlorine dioxide automatic generating and mixing disinfection device having a first raw material tank, a second raw material tank, a reactor, a water injector and a check valve; the first and the second raw material tanks and the reactor are sealed container on which there are raw material inlets and discharge holes, one raw material inlet is connected to the first raw material tank by a first pick-up tube which connects with a first titration valve, the other is connected to the second raw material tank by a second pick-up tube which connects with a second titration valve; the reactor discharging hole is connected to the water injector inlet, the check valve is installed in the connecting pipe.

Abstract: The present invention is generally related to a device and method for sanitizing a medical instrument with ozone, in particular the invention relates to a system, method and a device for sanitizing a continuous positive airway pressure (CPAP) device. The device has an ozone compartment, an ozone operating system and one or more ozone distribution lines that distribute ozone to a continuous positive airway pressure device. The device may further include a heater adapter unit to connect heating systems in CPAP devices while distributing ozone to sanitize the CPAP device in accordance with the present invention.

Abstract: A PET bottle sterilization apparatus is for consecutively sterilizing multiple PET bottles (B) while conveying them, and includes a hydrogen peroxide introducing means (5) for introducing hydrogen peroxide into a PET bottle (B) so as to sterilize its interior and a hot air supplying means (6) for introducing hot air into the sterilized PET bottle (B) so as to eliminate hydrogen peroxide remaining inside it. This apparatus includes a plasma introducing means (P) for introducing plasma into a PET bottle (B) by injecting plasma through a nozzle at at least one time point among a time point before hydrogen peroxide is introduced into the PET bottle (B), a time point after hydrogen peroxide was introduced into the PET bottle (B) and furthermore before hot air is introduced into the PET bottle (B), and a time point after hot air was introduced into the PET bottle (B).

Abstract: A decontamination system (10), including: a plurality of interconnected and insulated panels (18) configured to form walls (14) and a roof (16) and to define an interior (24) of an enclosure (12) configured to enclose a transportation asset; a humidifying module (30) in fluid communication with the interior of the enclosure and configured to raise a temperature and a humidity of the interior of the enclosure to a predetermined temperature level and a predetermined humidity level for a timed duration; and a dehumidifying module (50) in fluid communication with the interior of the enclosure and configured to lower the temperature and the humidity of the interior of the enclosure from the predetermined temperature level and the predetermined humidity level to ambient levels.